Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences executive Daveen Chopra, CVP TMTT & Surgical, reported routine equity compensation and related tax withholding transactions in company stock. On May 7, 2026, he received 9,675 restricted stock units and 9,675 performance-based rights, plus 49,100 stock options with an $82.76 exercise price, all granted under the Long-Term Stock Incentive Compensation Program.
The restricted stock units and options are scheduled to vest in four equal annual installments starting one year after the grant date, while the performance rights are scheduled to vest on May 7, 2029 based on three-year performance goals, with 0%–200% of the target potentially vesting. On May 7–8, 2026, a total of 1,815 shares of common stock were disposed of solely to cover tax obligations, not as open-market sales. After these transactions, Chopra directly holds 39,779 shares of common stock.
Edwards Lifesciences Corp executive Annette Bruls, CVP EMEACLA, received new equity awards and had a small tax-related share disposition. On May 7, 2026, she was granted 6,650 performance-based restricted stock units and 33,700 employee stock options tied to common stock.
The options have a conversion/exercise price of $82.76 per share and both the options and time-based restricted stock units vest in four equal annual installments starting one year after the grant date. The performance-based units, with a target of 6,650 shares, are scheduled to vest on May 7, 2029 based on performance over a three-year period, with payouts ranging from 0% to 200% of the target.
On May 8, 2026, 84 shares of common stock were disposed of at $82.76 per share to satisfy tax obligations, not as an open-market sale. Following these transactions, Bruls directly holds 20,737 shares of Edwards Lifesciences common stock.
Edwards Lifesciences Corporation reported results from its 2026 annual stockholders meeting. Stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program, increasing the total shares of common stock available under the plan by 7,000,000 to 341,500,000 shares.
All director nominees were elected with strong majorities, and stockholders approved the advisory vote on named executive officer compensation. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the amended and restated long-term stock incentive program.
Edwards Lifesciences reported higher first-quarter 2026 results, led by growth in structural heart therapies. Net sales from continuing operations rose to $1.65 billion from $1.41 billion, driven mainly by Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT).
Net income attributable to the company increased to $380.7 million from $358.0 million, and diluted earnings per share from continuing operations were $0.66 versus $0.62 a year earlier. Strong operating income of $477.6 million included higher litigation expenses and a $123.6 million non-operating impairment tied to an earlier medical-device investment, partially offset by a $65.2 million gain on remeasurement of a previously held interest.
The company generated $43.8 million in operating cash flow, spent heavily on share repurchases including a $500 million accelerated share repurchase, and ended the quarter with $2.45 billion in cash and cash equivalents. It also completed the $128.9 million acquisition of Autus Valve Technologies to expand its pediatric pulmonary valve pipeline while continuing to navigate multiple tax and patent disputes with recorded legal accruals.
Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem exercised employee stock options to acquire 13,000 shares of common stock at $59.2567 per share. These options related to an award exercisable since May 8, 2020 and expiring on May 7, 2026, and the filing shows this option position is now fully exercised.
To cover tax obligations, the company withheld 11,131 shares at $82.91 and 620 shares at $83.98, reported as tax-withholding dispositions rather than open-market sales. After these transactions, Ullem directly owns 40,948 shares and indirectly holds 266,318 shares of common stock through a trust.
Edwards Lifesciences CEO Bernard J. Zovighian reported routine share dispositions mainly related to gifts and tax withholding. On May 5, 2026, he made two bona fide gifts of common stock, transferring 523 shares from a trust and 523 shares from his direct holdings, both at a stated price of $0.00 per share, reflecting that no consideration was received. Earlier, on May 3, 2026, 515 shares were disposed of at $83.98 per share to satisfy tax obligations, a tax-withholding disposition rather than an open-market sale. Following these transactions, he continues to hold 80,257.6499 direct shares, 12,039.5511 shares indirectly through a trust, and 3,733.5603 shares indirectly in a 401(k) plan.
Edwards Lifesciences Corp CVP, TAVR Daniel J. Lippis reported option exercises, tax withholding, and open-market sales of company stock. On May 1, 2026, he exercised employee stock options for 1,019 shares at $59.2567 per share and sold 1,000 shares at $82.9889 plus 19 shares at $83.9880. On May 4, 2026, he exercised options for another 1,019 shares at $59.2567 and sold 1,019 shares at $83.98. A separate 252-share disposition on May 3, 2026 covered tax obligations. After these transactions, he directly held about 33,681.9103 shares of Edwards Lifesciences common stock. The filing notes all reported trades were effected under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Corp executive Daveen Chopra reported a routine tax-related share disposition. On the transaction date, 282 shares of common stock were withheld at $83.98 per share to cover tax obligations, leaving Chopra with 31,919 shares of Edwards Lifesciences common stock held directly after the transaction.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, reported routine share updates and a small tax-related disposition of company stock. The filing shows a tax-withholding disposition of 469 shares of common stock at $83.98 per share, leaving him with 20,797.2532 shares held directly.
The filing also reports indirect holdings of 121,756 common shares held by a trust and 38,969.5756 shares represented in a 401(k) plan account, based on the plan administrator’s most recent statement. Overall, this Form 4 reflects mainly administrative updates and tax withholding rather than open-market buying or selling.
Edwards Lifesciences Corporation filed a Form 8-K announcing that Theodora (“Doretta”) Mistras has been appointed Corporate Vice President and Chief Financial Officer, effective May 29, 2026, succeeding Scott B. Ullem. The company highlights her prior experience as CFO of Viatris and senior roles in healthcare investment banking.
Under her offer letter, Mistras will receive a base salary of $925,000, a target annual bonus of at least 100% of base salary under the Edwards Lifesciences Incentive Plan, and a $2,013,000 sign-on bonus subject to pro-rata repayment if she departs within 24 months in certain circumstances. She will also receive $8,000,000 in restricted stock units vesting over three years, an initial 2026 annual equity award valued at $4,500,000, severance protections of at least one times salary and target bonus plus a pro-rated bonus and $50,000 in outplacement benefits, and reimbursement of up to $15,000 in legal fees and relocation costs.